- Human Liver Microsomes
- Tissue Fractions－挑選指南
Human Liver Microsomes 在以下研究中扮演核心角色：
l Metabolic stability
l Reactive metabolite detection
l Drug–drug interaction (DDI)
l Reaction phenotyping
l Metabolite identification
|
產品格式 |
Fraction 類型 |
主要酵素組成 |
核心用途 |
主要特色 |
|
UltraPool™ HLM 150 |
Liver Microsomes |
CYP, UGT, FMO |
Metabolic stability、DDI、reaction phenotyping、metabolite identification |
全球首個 150 donor pooled HLM；代表平均族群與 CYP polymorphism；lot-to-lot CV <5–10%；支援 multi-year programs |
|
Human Liver Microsomes (HLM) |
Liver Microsomes |
CYP, UGT, FMO |
Drug metabolism、reactive metabolites、DDI、phenotyping |
Native enzyme 來源；方便且具成本效益；可單 donor 或 pooled |
|
Human S9 Fraction |
Microsomes + Cytosol |
Phase I + Phase II enzymes |
Phase I/II metabolism screening |
同時含 microsomes 與 cytosol；一次評估完整代謝路徑 |
|
Human Cytosol |
Cytosol |
GST, NAT, SULT |
Phase II metabolism |
含 soluble phase II enzymes；補強 glucuronidation 以外路徑 |
|
Mixed Pooled Human Intestinal Microsomes |
Intestinal Microsomes |
CYP3A4, CYP2C9, UGT1A/8/10, CES |
Intestinal metabolism |
來自十二指腸+空腸；用於 first-pass metabolism 評估 |
|
Animal Liver Microsomes |
Liver Microsomes |
CYP + Phase II |
Preclinical metabolism comparison |
Mouse / Rat / Dog / Monkey；用於物種選擇 |
|
Animal S9 / Cytosol |
S9 / Cytosol |
Phase I + II / Phase II |
Mechanistic metabolism studies |
與 human 同等品質與 characterization；適用 stability、metabolite ID |